Pleurodynia Treatment - Global Strategic Business Report

The global market for Pleurodynia Treatment was estimated at US$96.6 Million in 2023, and is projected to reach US$120.0 Million by 2030, growing at a CAGR of 3.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the pleurodynia treatment market is driven by several factors. Firstly, increased awareness and better diagnostic capabilities have led to more frequent and accurate identification of pleurodynia, boosting demand for effective treatments. Secondly, advancements in pharmaceutical research have resulted in the development of more potent and targeted NSAIDs and pain management solutions, enhancing patient outcomes. The rise in the global incidence of viral infections, partly due to population growth and increased travel, has also contributed to market expansion. Furthermore, improved healthcare infrastructure, particularly in emerging economies, has made access to treatment more widespread. The trend towards personalized medicine and tailored treatment plans has encouraged the development of specialized therapies for pleurodynia. Lastly, strategic collaborations between pharmaceutical companies and research institutions are accelerating the discovery of novel treatment options, ensuring a steady pipeline of new therapies entering the market.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Painkillers Therapy segment, which is expected to reach US$70.3 Million by 2030 with a CAGR of a 3.5%. The Immunoglobulin Therapy segment is also set to grow at 2.7% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, estimated at $26.3 Million in 2023, and China, forecasted to grow at an impressive 6.1% CAGR to reach $24.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Pleurodynia Treatment Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pleurodynia Treatment Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Pleurodynia Treatment Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Algen Healthcare Ltd., AstraZeneca PLC, Bayer AG, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

Algen Healthcare Ltd.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Co., Ltd.
Estrellas Life Sciences Pvt. Ltd.
GSK Plc
Healthy Life Pharma (P) Ltd.
Horizon Therapeutics plc
Lifecare Neuro Products Ltd.
Novartis AG
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Zyla Life Sciences;

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Global Economic Update
Pleurodynia Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Growing Awareness of Pleurodynia Throws the Spotlight on Treatment Demand
Advancements in Diagnostic Technologies Propel Growth in Pleurodynia Treatment Market
Rising Incidence of Viral Infections Generates Demand for Effective Treatments
Expanding Research in Antiviral Therapies Sustains Growth in Treatment Options
Growing Popularity of Non-Invasive Treatment Methods Spurs Market Expansion
Pharmaceutical Investments in Novel Drug Development Enhance Market Opportunities
Increasing Incidence of Post-Viral Syndromes Expands Addressable Market Opportunity

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Pleurodynia Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
Table 3: World Historic Review for Pleurodynia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 4: World 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Painkillers Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
Table 6: World Historic Review for Painkillers Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 7: World 16-Year Perspective for Painkillers Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Immunoglobulin Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Immunoglobulin Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Immunoglobulin Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
Table 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 20: USA Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 21: USA Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 22: USA 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 23: USA Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 24: USA Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 25: USA 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

CANADA

Table 26: Canada Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 27: Canada Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 28: Canada 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 29: Canada Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 30: Canada Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 31: Canada 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

JAPAN

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 32: Japan Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 33: Japan Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 34: Japan 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 35: Japan Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 36: Japan Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 37: Japan 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

CHINA

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 38: China Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 39: China Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 40: China 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 41: China Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 42: China Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 43: China 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

EUROPE

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 44: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
Table 45: Europe Historic Review for Pleurodynia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 46: Europe 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 47: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 48: Europe Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 49: Europe 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 50: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 51: Europe Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 52: Europe 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

FRANCE

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 53: France Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 54: France Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 55: France 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 56: France Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 57: France Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 58: France 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

GERMANY

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 59: Germany Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 60: Germany Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 61: Germany 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 62: Germany Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 63: Germany Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 64: Germany 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

ITALY

Table 65: Italy Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 66: Italy Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 67: Italy 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 68: Italy Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 69: Italy Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 70: Italy 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

UNITED KINGDOM

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 71: UK Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 72: UK Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 73: UK 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 74: UK Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 75: UK Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 76: UK 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

SPAIN

Table 77: Spain Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 78: Spain Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 79: Spain 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 80: Spain Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 81: Spain Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 82: Spain 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

RUSSIA

Table 83: Russia Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 84: Russia Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 85: Russia 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 86: Russia Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 87: Russia Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 88: Russia 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 89: Rest of Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 90: Rest of Europe Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 91: Rest of Europe 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 92: Rest of Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 93: Rest of Europe Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 94: Rest of Europe 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
Table 96: Asia-Pacific Historic Review for Pleurodynia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 97: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 99: Asia-Pacific Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 100: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
Table 102: Asia-Pacific Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
Table 103: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

AUSTRALIA

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)

INDIA

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)

ARGENTINABRAZILMEXICOREST OF LATIN AMERICA

MIDDLE EAST

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)

IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST

AFRICA

Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)

IV. COMPETITION

Companies Mentioned

Algen Healthcare Ltd.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Co., Ltd.
Estrellas Life Sciences Pvt. Ltd.
GSK Plc
Healthy Life Pharma (P) Ltd.
Horizon Therapeutics plc
Lifecare Neuro Products Ltd.
Novartis AG
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Zyla Life Sciences;

Table Information

Report Attribute	Details
No. of Pages	270
Published	November 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 96.6 Million
Forecasted Market Value ( USD ) by 2030	$ 120 Million
Compound Annual Growth Rate	3.1%
Regions Covered	Global
No. of Companies Mentioned	15

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5471EUR$5,600USD£4,568GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10396EUR$10,640USD£8,679GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16414EUR$16,800USD£13,703GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 86 Featured):

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Pleurodynia Treatment Market by Diagnosis, Treatment, Mode Of Administration, End-User - Global Forecast 2025-2030

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

Alpha 1 Antitrypsin Deficiency Treatment - Global Strategic Business Report

Pulmonary Fibrosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Nasal Polyps Treatment Global Market Report 2024